

Oxytocin-receptor-expressing neurons in the parabrachial nucleus regulate fluid intake

Philip J. Ryan^{1,2,3*}, Silvano I. Ross^{1,2}, Carlos A. Campos^{1,2}, Victor A. Derkach^{1,2} and Richard D. Palmiter^{1,2*}

Brain regions that regulate fluid satiation are not well characterized, yet are essential for understanding fluid homeostasis. We found that oxytocin-receptor-expressing neurons in the parabrachial nucleus of mice (*Oxtr*^{PBN} neurons) are key regulators of fluid satiation. Chemogenetic activation of *Oxtr*^{PBN} neurons robustly suppressed noncaloric fluid intake, but did not decrease food intake after fasting or salt intake following salt depletion; inactivation increased saline intake after dehydration and hypertonic saline injection. Under physiological conditions, *Oxtr*^{PBN} neurons were activated by fluid satiation and hypertonic saline injection. *Oxtr*^{PBN} neurons were directly innervated by oxytocin neurons in the paraventricular hypothalamus (*Oxt*^{PVH} neurons), which mildly attenuated fluid intake. Activation of neurons in the nucleus of the solitary tract substantially suppressed fluid intake and activated *Oxtr*^{PBN} neurons. Our results suggest that *Oxtr*^{PBN} neurons act as a key node in the fluid satiation neurocircuitry, which acts to decrease water and/or saline intake to prevent or attenuate hypervolemia and hypernatremia.

The neuropeptide oxytocin has well-recognized roles in lactation, parturition and social interaction¹. Pharmacological studies have shown that oxytocin also decreases ingestive behaviors, including feeding, drinking and salt intake^{2–5}, and increases renal NaCl excretion after a salt load in rodents^{6–8}. This suggests that oxytocin regulates fluid homeostasis, which requires tight control of both NaCl and water to maintain extracellular fluid (ECF) volume and osmolarity^{9–12}. ECF volume is proportional to total body sodium content, whereas osmolarity is regulated by the ingestion and excretion of water and sodium^{9–12}.

Oxytocin-expressing neurons are located in the paraventricular nucleus of the hypothalamus (PVH) and supraoptic nucleus (SON) and project axons to the posterior pituitary to release oxytocin peripherally¹. The PVH also contains oxytocin-expressing neurons that project within the CNS¹. The oxytocin receptor (*Oxtr*) is expressed in several brain regions and is responsible for mediating the central effects of oxytocin^{1,13}.

To evaluate the role of oxytocin-related neural circuitry on ingestive behaviors, we generated mice expressing Cre recombinase at the *Oxtr* locus (Supplementary Fig. 1). A recent study demonstrated that optogenetic stimulation of *Oxtr*-expressing neurons in the arcuate nucleus decreases feeding¹⁴. Here we focused on *Oxtr*-expressing neurons in the parabrachial nucleus, a brain region that is known to modulate ingestive behaviors^{15–19}. We found that *Oxtr*^{PBN} neurons are important regulators of fluid intake.

Results

***Oxtr* is expressed in the PBN.** To examine where *Oxtr* is expressed in the mouse brain, we bred *Oxtr*^{Cre/+} mice with Cre-dependent TdTomato reporter (Ai14) mice. We observed robust TdTomato expression in the dorsolateral (dl) and external lateral (el) parabrachial nucleus (PBN) (649 ± 39 *Oxtr*^{PBN} neurons per brain) and several other brain regions (Fig. 1a and Supplementary Fig. 2a,b). We confirmed adult expression of *Oxtr* by injecting adeno-associated virus (AAV) carrying Cre-dependent mCherry

(AAV1-DIO-mCherry) into the PBN of adult *Oxtr*^{Cre/+} mice and by in situ hybridization for *Oxtr* mRNA in *Oxtr*^{Cre/+}::Ai14 mice (Fig. 1b and Supplementary Fig. 2c). To characterize the effects of oxytocin on *Oxtr*^{PBN} neurons, we recorded the activity of fluorescently labeled cells in brain slices and observed that bath application of Thr₄Gly₇-oxytocin (TGOT), a selective *Oxtr* agonist, efficiently activated *Oxtr*^{PBN} neurons, and this activation was blocked by coadministration of atosiban (oxytocin-receptor antagonist), which confirmed the specificity of the activation (Fig. 1c and Supplementary Fig. 2d).

***Oxtr*^{PBN} neuron activation suppresses noncaloric fluid intake.** We initially asked whether activating *Oxtr*^{PBN} neurons modulated feeding behavior. We bilaterally injected AAV carrying a Cre-dependent hM₃Dq:mCherry (AAV1-DIO-hM₃Dq:mCherry)²⁰ into the PBN of *Oxtr*^{Cre/+} mice (Fig. 1d) and chemogenetically activated the neurons by injecting the synthetic ligand clozapine-*N*-oxide (CNO, 1 mg kg⁻¹, intraperitoneally, ip), 30 min before the dark cycle or following a 24-h fast. We observed no significant difference in food intake compared to controls injected with AAV1-DIO-mCherry (Fig. 1e).

We also investigated the effect of *Oxtr*^{PBN} activation on fluid homeostasis. To assess both ECF volume and osmolarity, we used a two-bottle choice task consisting of water and 0.3 M NaCl (saline)^{17,19} and fed mice a sodium-depleted diet²¹. The molarity of total fluid intake under control conditions was ~0.15 M NaCl (equivalent to normal saline). Chemogenetic activation of *Oxtr*^{PBN} neurons after 24-h fluid deprivation suppressed total fluid intake (both water and 0.3 M NaCl) at the start of the dark cycle (Fig. 1f). After ~4h, there was a rebound such that the cumulative overnight NaCl intake was not significantly different between hM₃Dq-expressing and control mice ($P = 0.5821$), and there was only a small difference in cumulative water intake ($P = 0.0394$; Supplementary Fig. 3a). To assess whether the presence of food affected fluid intake, we stimulated *Oxtr*^{PBN} neurons after 24h of fluid deprivation and then denied

¹Howard Hughes Medical Institute, University of Washington, Seattle, Washington, USA. ²Department of Biochemistry, University of Washington, Seattle, Washington, USA. ³The Florey Institute of Neuroscience and Mental Health, University of Melbourne, Parkville, Victoria, Australia.

*e-mail: philip.ryan@florey.edu.au; palmiter@uw.edu




Fig. 1 | OxtR^{PBN} activation suppresses fluid but not food intake. **a, b**, TdTomato expression in PBN of *OxtR^{Cre/+}::Ai14* reporter mice ($n = 3$; **a**) and adult expression of mCherry fluorescence in *OxtR^{PBN}* neurons (**b**) following injection of AAV-DIO-mCherry in a 9-week-old *OxtR^{Cre/+}* male mouse ($n = 7$). dl, dorsolateral; el, external lateral; scp, superior cerebellar peduncle. Scale bar represents 100 μm . **c**, Representative example of electrophysiological activity in an *OxtR^{PBN}* neuron using cell-attached configuration. We observed increased spiking after application of the OxtR agonist TGOT (0.2 μM), which was inhibited by coadministration of the OxtR antagonist atosiban (1 μM ; the same neuron) ($n = 4$ of 4 *OxtR^{PBN}* neurons). **d**, Injection of AAV-DIO-hM₃Dq:mCherry in *OxtR^{PBN}* neurons. Gray and black triangles denote *loxP* and *lox2722* sites, respectively. **e–i**, Acute *OxtR^{PBN}* activation with CNO revealed no significant change in food intake at baseline or after 24 h of fasting ($n = 7$ per group; two-way repeated measures (RM) ANOVA; baseline food: interaction $F(8,96) = 0.2901$, $P = 0.9678$; 24-h fast: interaction $F(8,96) = 1.143$, $P = 0.3424$) (**e**); decreased water and NaCl consumption following 24-h dehydration in the presence of food ($n = 7$ per group; two-way RM ANOVA; NaCl: interaction $F(8,96) = 12.63$, $P < 0.0001$; water: interaction $F(8,96) = 39.75$, $P < 0.0001$) (**f**) and in the absence of food ($n = 6$ per group; two-way RM ANOVA; NaCl: interaction $F(8,80) = 8.173$, $P < 0.0001$; water: interaction $F(8,80) = 22.31$, $P < 0.0001$) (**g**); decreased water consumption at baseline ($n = 7$ per group; three-way mixed design ANOVA; NaCl: interaction $F(2.875,34.501) = 1.593$, $P = 0.210$; water: interaction $F(2.099,25.183) = 4.464$, $P = 0.021$) (**h**); and no significant change in Ensure or water intake following 24 h of caloric deprivation ($n = 6$ hM₃Dq, 7 mCherry; two-way RM ANOVA; Ensure: interaction $F(8,88) = 0.3809$, $P = 0.9282$; water: interaction $F(8,88) = 0.5037$, $P = 0.8505$). Data are expressed as mean \pm s.e.m. mCh, mCherry; veh, vehicle. **** $P < 0.0001$; *** $P < 0.001$; ** $P < 0.01$; * $P < 0.05$. See Supplementary Table 2 for statistical analyses.

them food. The mice expressing hM₃Dq decreased both water and NaCl intake, similarly to when food was present; however, control (mCherry-expressing) mice drank less water but drank more NaCl

when food was absent (Fig. 1g and Supplementary Fig. 3b). We also investigated the effects of OxtR^{PBN} stimulation at the start of the dark cycle without prior fluid deprivation. We observed a significant




Fig. 2 | OxtR^{PBN} activation decreases food intake in dehydrated mice and suppresses water intake following 48-h salt depletion and thirst-inducing conditions. **a**, Acute OxtR^{PBN} stimulation decreases food intake when mice are dehydrated ($n = 6$ hM₃Dq, 7 mCherry; two-way RM ANOVA; interaction $F(4,44) = 7.143$, $P = 0.0002$). **b–e**, Acute OxtR^{PBN} stimulation also decreases water, but not NaCl, consumption following 48-h salt depletion ($n = 7$ /group; two-way RM ANOVA; NaCl: interaction $F(8,96) = 1.408$, $P = 0.2028$; water: interaction $F(8,96) = 35.57$, $P < 0.0001$) (**b**), 0.5 M saline ip injection ($n = 7$ /group; two-way RM ANOVA; NaCl: interaction $F(4,48) = 0.08955$, $P = 0.9853$; water: interaction $F(4,48) = 11.37$, $P < 0.0001$) (**c**), 1 M mannitol ip injection ($n = 7$ /group; two-way RM ANOVA; NaCl: interaction $F(4,48) = 3.638$, $P = 0.0114$; water: interaction $F(4,48) = 24.56$, $P < 0.0001$) (**d**) and 30% PEG sc injection ($n = 6$ hM₃Dq, 7 mCherry; two-way RM ANOVA; NaCl: interaction $F(4,44) = 0.4042$, $P = 0.8046$; water: interaction $F(4,44) = 11.54$, $P < 0.0001$) (**e**). **f**, Following CNO administration, Fos was robustly expressed in OxtR^{PBN} and adjacent neurons in hM₃Dq-injected mice. Scale bar represents 100 μm. Data are expressed as mean \pm s.e.m. **** $P < 0.0001$; *** $P < 0.001$; ** $P < 0.01$; * $P < 0.05$. See Supplementary Table 2 for statistical analyses.

decrease in water intake in hM₃Dq-expressing mice compared with controls following CNO, but not vehicle, whereas NaCl intake was not significantly different, although intake was low (Fig. 1h). There was no significant difference in cumulative overnight intake of NaCl ($P = 0.2038$) or water ($P = 0.6645$) in hM₃Dq- or mCherry-expressing mice (Supplementary Fig. 3c).

Because OxtR^{PBN} stimulation decreased fluid but not food intake, we stimulated OxtR^{PBN} neurons during intake of a liquid diet of Ensure nutrition drink. After 24-h of caloric deprivation, intake of Ensure and water was unaffected (Fig. 1i), indicating that OxtR^{PBN} stimulation does not decrease the intake of all liquids. Apparently, the highly palatable nature of Ensure overrode the ability of OxtR^{PBN} stimulation to suppress fluid intake. Because mice drank only minimal water in this experiment, we repeated it, but returned fixed amounts of Ensure (1.6 or 0.7 ml); however, both hM₃Dq- and mCherry-expressing mice still drank limited amounts of water (Supplementary Fig. 3d,e), suggesting that the presence of even small amounts of Ensure decreases concurrent water intake. We assessed the effects of activating OxtR^{PBN} neurons on food intake during mild dehydration and observed decreased food intake (control diet) in hM₃Dq-injected mice (Fig. 2a), suggesting that OxtR^{PBN} neurons may be involved in mediating dehydration-induced anorexia²².

We also examined the effect of OxtR^{PBN} stimulation after salt depletion by injecting mice on a sodium-depleted diet with the diuretic furosemide (40 mg kg⁻¹ ip, twice, 1 d apart) and removing access to saline (0.3 M NaCl) for 48 h. OxtR^{PBN} stimulation suppressed water, but not NaCl, intake (Fig. 2b), suggesting that it does not suppress salt appetite. We also assessed the effect of OxtR^{PBN} stimulation after generating thirst by two different mechanisms: increasing osmolarity and inducing volume loss^{9,11}. To increase osmolarity, we injected hypertonic 0.5 M NaCl or equiosmolar 1 M mannitol ip²³; whereas we induced volume loss by injecting 30% polyethylene glycol (PEG) subcutaneously, which progressively draws out ECF without affecting osmolarity⁵. We observed that OxtR^{PBN} stimulation suppressed water intake after hypertonic saline injection in hM₃Dq- versus mCherry-injected mice (Fig. 2c); however, there was no significant difference in overnight water intake ($P = 0.2008$), suggesting a rebound effect in fluid intake (Supplementary Fig. 3f). OxtR^{PBN} stimulation also decreased fluid intake after mannitol and PEG injections (Fig. 2d,e). Throughout the experiments, we observed that mice retained similar daily baseline NaCl and water intake (Supplementary Fig. 3g). Following experimentation, we confirmed the targeting and activation of OxtR^{PBN} neurons by injecting CNO 2 h before perfusion, and we observed Fos expression in 72 \pm 4% of hM₃Dq-expressing




Fig. 3 | *OxtR^{PBN}* neuron inhibition increases NaCl intake after dehydration, after hypertonic saline injection and at baseline. **a, Injection of AAV1-DIO-GFP:TetTox in *OxtR^{PBN}* neurons. **b–d**, Chronic *OxtR^{PBN}* inactivation increased NaCl consumption after 24-h fluid deprivation ($n=6$ TetTox, 7 YFP; two-way RM ANOVA; NaCl: interaction $F(4,44)=5.704$, $P=0.0009$; water: interaction $F(4,44)=0.7961$, $P=0.5342$) (**b**) and after 0.5 M saline ip injection ($n=6$ TetTox, 7 YFP; two-way RM ANOVA; NaCl: interaction $F(4,44)=5.497$, $P=0.0011$; water: interaction $F(4,44)=0.1334$, $P=0.9693$) (**c**), but not after 48-h salt depletion ($n=6$ TetTox, 7 YFP; two-way RM ANOVA; NaCl: interaction $F(8,88)=0.4136$, $P=0.9100$; water: interaction $F(8,88)=0.8966$, $P=0.5230$) (**d**). **e**, Injection of AAV1-DIO-hM₄Di:mCherry in *OxtR^{PBN}* neurons. **f**, Acute *OxtR^{PBN}* inhibition increased baseline NaCl intake at the start of the dark cycle ($n=5$ hM₄Di, 6 mCherry; three-way mixed design ANOVA; NaCl: interaction $F(2,644,23,797)=4.305$, $P=0.018$; water: interaction $F(1,451,13,062)=0.790$, $P=0.436$). Data are expressed as mean \pm s.e.m. **** $P < 0.0001$; *** $P < 0.001$; ** $P < 0.01$; * $P < 0.05$. See Supplementary Table 2 for statistical analyses.**

neurons (and some adjacent neurons) in the PBN (Fig. 2f and Supplementary Fig. 3h).

***OxtR^{PBN}* neurons are necessary for protection against hypernatremia.** To ascertain whether *OxtR^{PBN}* neurons are necessary for fluid regulation, we chronically inactivated them by bilaterally injecting AAV carrying a Cre-dependent tetanus toxin light chain (AAV1-DIO-GFP:TetTox)²⁴ or control (AAV1-DIO-YFP) into the PBN of *OxtR^{Cre/+}* mice (Fig. 3a and Supplementary Fig. 4a,b). We found no significant difference in baseline NaCl preference at 0.075 M ($P=0.6292$), 0.3 M ($P=0.3364$) or 0.5 M ($P=0.9224$) (Supplementary Fig. 4c), and no substantial difference in baseline fluid intake after vehicle injection, either acutely (2 h) or overnight (Supplementary Fig. 4d,e). Following 24-h fluid deprivation, however, we observed increased NaCl, but not water, intake in TetTox-injected mice (Fig. 3b), which remained increased overnight, suggesting a longer term effect on fluid intake than that for hM₄Di-injected mice (Supplementary Fig. 4f). We also observed increased 0.3 M NaCl intake after hypertonic (0.5 M) saline ip injection, but not after salt depletion or other tests of fluid intake (Fig. 3c,d and Supplementary Fig. 4g,h). Following experimentation, we observed no significant correlation between TetTox-GFP expression and fluid

intake (for NaCl, $P=0.5408$; for water, $P=0.3905$; Supplementary Fig. 4i). Overall, these results suggest that *OxtR^{PBN}* neuron activity prevents excessive NaCl ingestion following dehydration and hypertonic saline injection.

We also investigated acute inhibition of *OxtR^{PBN}* neurons by injecting AAV carrying a Cre-dependent hM₄Di:mCherry transgene (AAV1-DIO-hM₄Di:mCherry)²⁰ bilaterally into the PBN (Fig. 3e and Supplementary Fig. 5a,b), and observed increased NaCl intake after CNO injection in hM₄Di-injected mice relative to controls at the start of the dark cycle (Fig. 3f). There was increased fluid intake (NaCl and water) after 24-h fluid deprivation, but the effect was less robust than that observed for TetTox-injected mice (Supplementary Fig. 5c). There was no difference in fluid intake during the light cycle, suggesting that acute *OxtR^{PBN}* inhibition does not spontaneously induce drinking, and there was no difference in feeding (Supplementary Fig. 5d,e). Following experimentation, we examined the extent of hM₄Di expression, but observed no significant correlation of expression with fluid intake (for NaCl, $P=0.2208$; for water, $P=0.2013$; Supplementary Fig. 5f).

***OxtR^{PBN}* neurons are activated under physiological conditions following fluid satiation and hypertonic saline.** To assess whether




Fig. 4 | OxtR^{PBN} neurons are activated physiologically by fluid and salt satiation and by hypertonic saline. **a**, Representative histological sections of Fos expression in OxtR^{Cre/+::Ai14} mice in caudal PBN from control, salt-depleted, fluid-depleted, 1 M saline-injected and normal saline-injected mice. Scale bar represents 100 μ m. **b–g** Quantification of caudal OxtR^{PBN} coexpression of Fos and OxtR in salt-depletion experiments ($n=4$ salt returned, 4 salt depleted, 3 control; one-way ANOVA; Fos/OxtR: interaction $F(2,7)=11.41$, $P=0.0063$; OxtR/Fos: interaction $F(2,7)=26.02$, $P=0.0006$) (**b,c**); fluid-deprivation experiments ($n=4$ fluid returned, 3 fluid deprived; unpaired two-tailed Student's t test; Fos/OxtR: $t(5)=4.285$, $P=0.0078$; OxtR/Fos: $t(5)=3.430$, $P=0.0186$) (**d,e**); and hypertonic saline injected experiments ($n=4$ for 1 M saline, 3 normal saline; unpaired two-tailed Student's t test; Fos/OxtR: $t(5)=4.033$, $P=0.0100$; OxtR/Fos: $t(5)=1.353$, $P=0.2341$) (**f,g**). **h**, Injection of AAV1-DIO-GCaMP6 in OxtR^{PBN} neurons. Gray and black triangles denote *loxP* and *lox2722* sites, respectively. **i**, Raster plot of normalized fluorescent Ca²⁺ activity during water bouts for each OxtR^{PBN} neuron ($n=94$ neurons in 3 mice). **j**, Raster plot of normalized fluorescent Ca²⁺ activity during Ensure bouts for each OxtR^{PBN} neuron ($n=85$ neurons in 3 mice). **k**, Raster plot of normalized fluorescent Ca²⁺ activity during bouts with an empty bottle for each OxtR^{PBN} neuron ($n=80$ neurons in 3 mice). **l**, Average OxtR^{PBN} fluorescent Ca²⁺ activity for water, Ensure and empty bottle. **m**, Average OxtR^{PBN} fluorescent Ca²⁺ activity comparing before bout versus after bout (two-way RM ANOVA: interaction $F(2, 257)=17.01$, $P<0.0001$). **n**, OxtR^{PBN} fluorescent Ca²⁺ activity following injection of CNO ip; $\Delta F/F = F - F_0/F_0$ ($n=83$ neurons in 2 mice; one-way RM ANOVA: interaction $F(8,656)=134.7$, $P<0.0001$; different letters denote significant difference from other columns). Data are expressed as mean \pm s.e.m. **** $P<0.0001$; *** $P<0.001$; ** $P<0.01$; * $P<0.05$. See Supplementary Table 2 for statistical analyses.




Fig. 5 | CGRP^{PBN} neuron activation decreases fluid and salt intake. **a**, Minimal colocalization of Oxt and CGRP in the PBN. Scale bar represents 200 μ m ($n=3$). **b**, Injection of AAV1-DIO-hM₃Dq:mCherry in CGRP^{PBN} neurons. **c–e** Acute CGRP^{PBN} activation with CNO produces a significant decrease in water consumption at baseline ($n=8$ hM₃Dq, 7 mCherry; three-way mixed design ANOVA; NaCl: interaction $F(1.876, 24.391) = 0.921$, $P = 0.406$; water: interaction $F(2.629, 34.177) = 3.768$, $P = 0.023$) (**c**) and after 24-h dehydration ($n=8$ hM₃Dq, 7 mCherry; two-way RM ANOVA; NaCl: interaction $F(8, 104) = 0.07589$, $P = 0.6395$; water: interaction $F(8, 104) = 22.22$, $P < 0.0001$) (**d**), and decreased NaCl and water consumption after 48-h salt depletion ($n=8$ hM₃Dq, 7 mCherry; two-way RM ANOVA; NaCl: interaction $F(8, 104) = 5.789$, $P < 0.0001$; water: interaction $F(8, 104) = 14.01$, $P < 0.0001$) (**e**). **f**, Following CNO, Fos is robustly expressed in external lateral CGRP^{PBN} neurons and in dorsolateral PBN in hM₃Dq-injected mice. Scale bar represents 200 μ m. Data expressed as mean \pm s.e.m. **** $P < 0.0001$; *** $P < 0.001$; ** $P < 0.01$; * $P < 0.05$. See Supplementary Table 2 for statistical analyses.

Oxt^{PBN} neurons are involved in fluid and salt intake under physiological conditions, we examined Fos expression in Oxt^{PBN} neurons of Oxt^{Cre/+::Ai14} mice following 48-h salt depletion or 24-h fluid deprivation. We observed significantly increased Fos expression in caudal Oxt^{PBN} neurons when NaCl and/or water were returned compared with control mice or mice that remained salt or water deprived, suggesting that Oxt^{PBN} neurons are activated following fluid satiation (Fig. 4a–e). There were no substantial differences in Fos expression in mid- and rostral-PBN populations, revealing differential activation throughout the PBN (Supplementary Fig. 6a–d). We also examined Fos expression under hypernatremic conditions by injecting 1 M NaCl ip into Oxt^{Cre/+::Ai14} mice. This treatment increased Fos expression in caudal Oxt^{PBN} neurons compared with 0.15 M NaCl (normal saline) injection (Fig. 4a, f, g and Supplementary Fig. 6e, f).

We assessed real-time Oxt^{PBN} neuron activity by injecting AAV1-DIO-GCaMP6m into the PBN of Oxt^{Cre/+} mice and measured calcium fluorescence after returning water to water-deprived mice (Fig. 4h and Supplementary Videos 1 and 2). We observed low fluorescence in Oxt^{PBN} neurons during dehydration, which remained low when the water spout was returned; however, we observed a rapid rise in Ca²⁺ fluorescence when mice began drinking, which decreased between bouts (Fig. 4i, l, m). This pattern was

observed in ~52% of Oxt^{PBN} neurons during water intake, but not during Ensure intake or when given an empty bottle, suggesting that Oxt^{PBN} neurons respond to noncaloric fluid ingestion, but not liquid diet or motor movements associated with licking (Fig. 4i–m). We co-injected AAV1-DIO-hM₃Dq:mCherry into two mice and observed increased calcium fluorescence within 5 min that peaked at ~15 min and lasted at least 2 h, corresponding to the time at which we observed substantial fluid inhibition behaviorally (Fig. 4n and Supplementary Video 3).

CGRP^{PBN} neurons have minimal overlap with Oxt^{PBN} neurons and decrease both food and fluid intake. We compared the expression pattern of neurons expressing Oxt or calcitonin-gene-related peptide (CGRP, which is encoded by *Calca* gene) in the PBN. CGRP^{PBN}-neuron stimulation is known to decrease feeding and mediate many aversive responses^{15,24}. We observed minimal co-expression of Oxt and CGRP in PBN neurons ($6 \pm 2\%$; Fig. 5a).

We investigated the effect of CGRP^{PBN} activation on fluid intake by injecting AAV1-DIO-hM₃Dq:mCherry into the PBN of *Calca*^{Cre/+} mice (Fig. 5b). CGRP^{PBN} activation with CNO decreased water, but not NaCl, intake at the start of the dark cycle (Fig. 5c) and after 24-h dehydration (Fig. 5d). Total fluid intake (combined water and NaCl) after 24-h dehydration was ~56% of that of control




Fig. 6 | Upstream and downstream projections of Oxt^{PBN} neurons. **a,b**, Injection of AAV1-DIO-synaptophysin:mCherry in Oxt^{PBN} neurons demonstrates downstream projections in central nucleus of amygdala (CeA), bed nucleus of stria terminalis (BNST), organum vasculosum of lamina terminalis (OVLT), anteroventral periventricular (AVPV) and median preoptic nuclei (MnPO) ($n=2$) (**b**). ac, anterior commissure. Scale bars represent 200 μm . **c**, Injection of AAV1-DIO-hM₃Dq:mCherry in Oxt^{PVH} neurons and AAV1-DIO-YFP into Oxt^{PBN} neurons. **d**, Projections of Oxt^{PVH} fibers to Oxt^{PBN} neurons. Scale bar represents 100 μm . **e,f**, Chemogenetic activation of Oxt^{PVH} neurons increases Fos in Oxt^{PVH} neurons (**e**) and Oxt^{PBN} neurons (**f**). 3V, third ventricle. Scale bar represents 100 μm ($n=3$). **g**, Injection of AAV1-DIO-ChR2:YFP in Oxt^{PVH} neurons and AAV1-DIO-mCherry into Oxt^{PBN} neurons. **h**, Action potentials evoked by 5-ms blue LED pulses at 20 Hz in an Oxt^{PBN} neurons in cell-attached configuration (three sweeps) ($n=5/23$ Oxt^{PBN} neurons). **i**, Synaptic currents evoked by 2-ms LED pulses in voltage-clamped Oxt^{PBN} neuron at -70 mV. 12 consecutive sweeps are shown, and they reveal a brief synaptic delay and sub-millisecond jitter (control). These EPSCs were inhibited in the presence of 20 μM CNQX and 50 μM D-AP5, antagonists of AMPA and NMDA glutamate receptors (red, five sweeps). The currents were recorded in the presence of 100 μM picrotoxin ($n=4$ of 13 Oxt^{PBN} neurons).

mice, whereas Oxt^{PBN} stimulation resulted in a total fluid intake of $\sim 29\%$ of that of control mice (Fig. 1f and Supplementary Table 1). After 48-h salt depletion, CGRP^{PBN} activation decreased both NaCl and water intake (Fig. 5e). Overall, these results suggest that CGRP^{PBN} stimulation inhibits all ingestive behaviors (food, fluid and salt), but is less effective than Oxt^{PBN} stimulation in decreasing fluid intake. We injected CNO 2 h before perfusion and observed Fos expression in $67 \pm 7\%$ of the hM₃Dq-expressing neurons, as

well as in non-hM₃Dq expressing neurons in the dorsolateral PBN, suggesting that CGRP^{PBN} neurons might activate dorsolateral PBN neurons (Fig. 5f).

Oxt^{PBN} neurons project to brain regions involved in fluid regulation. To investigate downstream projections of Oxt^{PBN} neurons, we injected AAV1-DIO-synaptophysin:mCherry into the PBN of Oxt^{Cre/+} mice, which revealed prominent projections to the




Fig. 7 | Oxt^{PVH} neuron activation attenuates water consumption. **a**, Injection of AAV1-DIO-hM₃Dq:mCherry in Oxt^{PVH} neurons. **b–d**, Acute Oxt^{PVH} activation revealed no significant change in NaCl or water consumption at baseline ($n=8$ hM₃Dq, 7 mCherry; three-way mixed design ANOVA; NaCl: interaction $F(1,749,22.735) = 0.748, P = 0.468$; water: interaction $F(2,480,32.236) = 1.250, P = 0.305$) (**b**), but water consumption was decreased after 24-h dehydration ($n=8$ hM₃Dq, 7 mCherry; two-way RM ANOVA; NaCl: interaction $F(8,104) = 0.1871, P = 0.9922$; water: interaction $F(8,104) = 3.456, P = 0.0014$) (**c**) and after 0.5 M saline ip ($n=8$ hM₃Dq, 7 mCherry; two-way RM ANOVA; NaCl: interaction $F(4,52) = 2.052, P = 0.1007$; water: interaction $F(4,52) = 5.763, P = 0.0006$) (**d**). **e**, Injection of AAV1-DIO-GFP:TetTox in Oxt^{PVH} neurons. **f**, Chronic inactivation of Oxt^{PVH} neurons increased NaCl and water consumption after vehicle injection ($n=6$ TetTox, 8 YFP; two-way RM ANOVA; NaCl: interaction $F(8,96) = 2.046, P = 0.0489$; water: interaction $F(8,96) = 5.036, P < 0.0001$). **g**, Injection of AAV1-DIO-hM₃Dq:mCherry in Oxt^{PVH} neurons and bilateral cannula implantation into PBN. **h**, Infusion of CNO into PBN decreased water consumption after 24-h dehydration ($n=6$ per group; two-way RM ANOVA; NaCl: interaction $F(8,80) = 0.1334, P = 0.9975$; water: interaction $F(8,80) = 2.108, P = 0.0444$). Data are expressed as mean \pm s.e.m. *** $P < 0.001$; ** $P < 0.01$; * $P < 0.05$. See Supplementary Table 2 for statistical analyses.

central nucleus of the amygdala, bed nucleus of the stria terminalis, organum vasculosum of the lamina terminalis (OVLT), anteroventral periventricular nucleus (AVPV) and median preoptic nucleus (MnPO) (Fig. 6a,b), and less prominent projections to other brain regions (Supplementary Fig. 7a,b). Many of these regions are activated following excessive fluid intake^{25,26}. By comparison, CGRP^{PBN} neurons do not project to the OVLT, AVPV or MnPO¹⁵, which are more selectively involved in regulating fluid intake^{9,27}.

Oxt^{PBN} neurons receive projections from Oxt^{PVH} neurons. Because Oxt^{PBN} activation suppressed fluid intake, we investigated

the effect of PVH oxytocin-expressing neurons (Oxt^{PVH}) on fluid intake^{1,28}. We confirmed projections from Oxt^{PVH} to Oxt^{PBN} neurons by injecting AAV1-DIO-hM₃Dq:mCherry into the PVH and AAV1-DIO-YFP into the PBN of Oxt^{Cre/+}::Oxt^{Cre/+} mice, which revealed mCherry-positive axon fibers in the PBN (Fig. 6c,d). After CNO injection, Fos expression increased in both Oxt^{PVH} and Oxt^{PBN} neurons, primarily in the caudal Oxt^{PBN} neurons (20 \pm 4%; Fig. 6e,f and Supplementary Fig. 7c). To ensure that the mCherry-positive axons were arising from Oxt^{PVH} and not Oxt^{PVH} neurons, we injected AAV1-DIO-synaptophysin:mCherry into the PVH of Oxt^{Cre/+} mice and observed no visible fibers in the




Fig. 8 | Activation of NTS or CCK^{NTS} neurons decreases fluid intake and activates Oxt^{PBN} neurons. **a**, Injection of AAV-hM₃Dq:mCherry in NTS and AAV-DIO-YFP in Oxt^{PBN} neurons. **b, c**, After 24-h dehydration, NTS activation suppressed NaCl and water consumption ($n = 6$ hM₃Dq, 5 DsRed; two-way RM ANOVA; NaCl: interaction $F(8,72) = 11.88$, $P < 0.0001$; water: interaction $F(8,72) = 17.94$, $P < 0.0001$) (**b**), as well as food intake ($n = 6$ hM₃Dq, 5 DsRed; two-way RM ANOVA; interaction: $F(4,36) = 91.69$, $P < 0.0001$) (**c**). **d**, Following CNO administration, Fos was robustly expressed in external lateral and dorsolateral PBN in hM₃Dq-injected mice in caudal and rostral PBN. Scale bar represents 100 μm . **e**, Injection of AAV-hM₃Dq:mCherry in CCK^{NTS} neurons. **f**, After 24-h dehydration, CCK^{NTS} activation decreased NaCl and water consumption ($n = 5$ hM₃Dq, 4 mCherry; two-way RM ANOVA; NaCl: interaction $F(8,56) = 3.047$, $P = 0.0065$; water: interaction $F(8,56) = 5.693$, $P < 0.0001$). **g**, RNAscope in situ hybridization image from *Cck^{Cre/+}* mice demonstrating coexpression of *Oxt* mRNA and *Fos* mRNA in PBN ($n = 3$). Scale bar represents 200 μm . **h**, CCK-8 (30 nM, horizontal bars) increases firing rate in 40% (2 of 5) of Oxt^{PBN} and 57% (4 of 7) of CGRP^{PBN} neurons. Amplitude scale is 50 pA and 100 pA for top and bottom traces, respectively. Data are expressed as mean \pm s.e.m. **** $P < 0.0001$; *** $P < 0.001$; ** $P < 0.01$; * $P < 0.05$. See Supplementary Table 2 for statistical analyses.

PBN (Supplementary Fig. 7d). We also injected AAV-DIO-hM₃Dq:mCherry into the PVH and AAV-DIO-YFP into the PBN of *Oxt^{Cre/+}* mice and observed minimal Fos expression in Oxt^{PBN} neurons after CNO (Supplementary Fig. 7e–g).

To ascertain whether Oxt^{PVH} neurons can directly activate Oxt^{PBN} neurons, we injected AAV1-DIO-ChR2:YFP into the PVH and AAV-DIO-mCherry into the PBN of *Oxt^{Cre/+}::Oxt^{Cre/+}* mice. Photoactivation (20 Hz) of Oxt^{PVH} axon terminals in the PBN resulted in spiking in 22% (5 of 23) of Oxt^{PBN} neurons. In a separate experiment, 4 of 13 Oxt^{PBN} neurons responded to photostimulation of Oxt^{PVH} fibers in PBN slices with evoked excitatory postsynaptic

currents (EPSCs) of short synaptic latency (3.5–5 ms) and sub-millisecond jitter (0.26 ± 0.024 ms), which is indicative of monosynaptic innervation. EPSCs were suppressed by inhibitors of AMPA and NMDA receptors, implicating glutamate as a neurotransmitter (Fig. 6g–i and Supplementary Fig. 7h).

Activation of Oxt^{PVH} neurons attenuates fluid intake. To assess the effect of Oxt^{PVH} activation on fluid intake, we injected AAV1-DIO-hM₃Dq:mCherry bilaterally into the PVH of *Oxt^{Cre/+}* mice (Fig. 7a). Oxt^{PVH} stimulation did not significantly attenuate baseline NaCl or water intake following CNO or vehicle injection in hM₃Dq-injected

or control mice (Fig. 7b); however, $Oxtr^{PVH}$ stimulation did attenuate water intake following 24-h fluid deprivation and osmolarity-induced thirst (hypertonic saline and mannitol) (Fig. 7c,d and Supplementary Fig. 7i), but not following salt depletion or volume depletion (PEG) (Supplementary Fig. 7j,k). These results suggest that $Oxtr^{PVH}$ stimulation attenuates fluid intake, but does so less robustly than $Oxtr^{PBN}$ stimulation. As previously reported, there was no significant difference in feeding at baseline ($P=0.9325$) or after fasting ($P=0.9670$)²⁹ (Supplementary Fig. 7l). Following CNO, we observed Fos expression in $64 \pm 5\%$ of hM_3Dq -expressing $Oxtr^{PVH}$ neurons (Supplementary Fig. 7m).

We also inactivated $Oxtr^{PVH}$ neurons by injecting AAV1-DIO-GFP:TetTox bilaterally to test whether these neurons have a physiological role in fluid intake similar to that of $Oxtr^{PBN}$ neurons (Fig. 7e and Supplementary Fig. 8a,b). $Oxtr^{PVH}$ inactivation revealed no substantial difference in 24-h baseline saline preference (Supplementary Fig. 8c); however, TetTox-injected mice increased fluid intake, particularly water intake, following vehicle injection at the start of the dark cycle and during several other tests of fluid intake (Fig. 7f and Supplementary Fig. 8d–h), suggesting that $Oxtr^{PVH}$ neurons have a role in reducing water intake under physiological conditions.

To assess the role of PBN projections from $Oxtr^{PVH}$ neurons, we injected AAV1-DIO- hM_3Dq :mCherry or AAV-DIO-mCherry bilaterally into the PVH of $Oxtr^{Cre/+}$ mice and implanted a bilateral cannula over the PBN (Fig. 7g and Supplementary Fig. 9a). Intra-PBN infusion of CNO (1 mM; 500 nl bilaterally) during the light cycle following 24-h fluid restriction decreased water intake in the hM_3Dq -injected mice compared with controls (Fig. 7h). For comparison, intraperitoneal CNO also decreased water intake following 24-h dehydration in the light cycle (Supplementary Fig. 9b). As with previous cohorts, there was no significant difference in baseline NaCl intake ($P=0.3627$) or water intake ($P=0.1763$) following CNO or vehicle ip injections at the start of the dark cycle (Supplementary Fig. 9c).

Following experimentation, we confirmed targeting and cannula placement (Supplementary Fig. 9d). To validate that delivery of CNO to the PBN activates $Oxtr^{PBN}$ neurons, we injected $Oxtr^{Cre/+};Oxtr^{Cre/+}$ mice with AAV1-DIO- hM_3Dq :mCherry in the PVH, AAV1-DIO-YFP in the PBN and a bilateral cannula over the PBN (Supplementary Fig. 9e). When mice were infused with CNO 2 h before perfusion, Fos was induced in $22 \pm 2\%$ $Oxtr^{PBN}$ neurons (Supplementary Fig. 9g), suggesting that the effect may be mediated either by projections of $Oxtr^{PVH}$ to $Oxtr^{PBN}$ neurons or by antidromic activation to $Oxtr^{PVH}$ cell bodies, which then activate axon collaterals projecting to other brain regions³⁰. We observed Fos expression in $26 \pm 8\%$ of $Oxtr^{PVH}$ neurons (Supplementary Fig. 9f), but only scattered, low-level Fos expression in the nucleus of the solitary tract (NTS) region, which receives projections from the PVH³¹ (Supplementary Fig. 9h). These data suggest that activation of $Oxtr^{PVH}$ projections to $Oxtr^{PBN}$ neurons provides a small attenuation of fluid intake, indicating that other neuronal inputs to $Oxtr^{PBN}$ neurons are required for more robust fluid suppression.

NTS neurons also suppress fluid intake and activate $Oxtr^{PBN}$ neurons. Previous research has suggested that the NTS and the adjacent area postrema modulate fluid intake and provide substantial input to the PBN^{9,11}. To investigate the effect of the medial NTS on fluid intake, we injected nonselective AAV- hM_3Dq :mCherry or control nonselective AAV-DsRed into the NTS of $Oxtr^{Cre/+}$ mice and AAV-DIO-YFP into the PBN to fluorescently label $Oxtr^{PBN}$ neurons (Fig. 8a and Supplementary Fig. 9i). Following 24-h dehydration, we activated NTS neurons with CNO and observed a large decrease in fluid (water and NaCl) and food intake in hM_3Dq -injected mice relative to controls (Fig. 8b,c). Mice did not display overt signs of distress or impaired movement. We injected CNO 2 h before perfusion and observed robust Fos expression in hM_3Dq -expressing

NTS neurons (Supplementary Fig. 9j,k) and in $33 \pm 6\%$ of $Oxtr^{PBN}$ neurons and other neurons in the dorsolateral and external lateral rostral PBN (Fig. 8d).

Previous studies have identified cholecystokinin (CCK) as a neuropeptide that decreases fluid intake following infusion into the PBN³². CCK is expressed in NTS neurons (CCK^{NTS}) that project to the PBN and decrease food intake by directly activating CGRP^{PBN} neurons³³. We investigated whether CCK^{NTS} neurons also decrease fluid intake by bilaterally injecting AAV1-DIO- hM_3Dq :mCherry into the NTS of $Cck^{Cre/+}$ mice (Fig. 8e and Supplementary Fig. 9l). Following 24-h dehydration, hM_3Dq -injected mice significantly decreased both NaCl and water intake (Fig. 8f). This decrease was not as robust as that evoked by $Oxtr^{PBN}$ stimulation, but was larger than that evoked by CGRP^{PBN} stimulation (Supplementary Table 1), suggesting that it is not merely mediated via CCK^{NTS} projections to CGRP^{PBN} neurons. We observed Fos expression in the NTS and in both the dorsolateral and external lateral PBN regions (Supplementary Fig. 9m,n). To investigate whether $Oxtr^{PBN}$ neurons were specifically activated, we performed *in situ* hybridization for *Fos* and *Oxtr* mRNA in hM_3Dq -injected mice and found that $19 \pm 2\%$ of $Oxtr^{PBN}$ neurons expressed *Fos* (Fig. 8g). We also observed that bath application of a CCK agonist, CCK-8 (30 nM), increased the firing rate in both $Oxtr^{PBN}$ and CGRP^{PBN} neurons (Fig. 8h), which is indicative of functional CCK receptors in both PBN populations.

A comparison of 2-h and 4-h fluid intake after stimulating each of the neuronal populations following 24-h dehydration revealed a range of effects on fluid consumption. From largest to smallest, the effects on total fluid intake were nonspecific NTS > $Oxtr^{PBN}$ > CC K^{NTS} > CGRP^{PBN} > $Oxtr^{PVH}$ (Supplementary Table 1). Of these, only $Oxtr^{PBN}$ and $Oxtr^{PVH}$ stimulation selectively decreased noncaloric fluid intake.

Discussion

Our results identify a population of $Oxtr$ -expressing neurons in the PBN that regulate noncaloric fluid intake. These neurons receive direct inputs from hypothalamic $Oxtr^{PVH}$ neurons, are activated by NTS neurons and project to several forebrain regions (Supplementary Fig. 10a). $Oxtr^{PBN}$ neurons are predominantly separate from CGRP^{PBN} neurons, which decrease both food¹⁵ and fluid intake (see Fig. 5), suggesting that distinct neuronal populations mediate different aspects of ingestive behaviors.

Under physiological conditions, we observed increased Fos expression in a subset of $Oxtr^{PBN}$ neurons (~20%) after rehydration, suggesting that these neurons are engaged in fluid satiation. Using calcium fluorescence, we observed real-time activity in $Oxtr^{PBN}$ neurons, which was low during dehydration and remained low before consumption, suggesting that $Oxtr^{PBN}$ neurons do not respond to anticipatory cues, unlike neurons that express agouti-related protein or vasopressin^{34,35}. Drinking water precipitated a rapid rise in $Oxtr^{PBN}$ calcium activity, which decreased between bouts, suggesting that these neurons interact with thirst-related neural circuits to adjust the overall level of fluid intake. We observed no difference in calcium activity for Ensure or for an empty bottle. One limitation of our study was that photobleaching of $Oxtr^{PBN}$ neurons occurred when the recording was extended, leaving us unable to quantitatively assess overall calcium activity changes over a prolonged period; however, qualitatively, calcium activity appeared to increase over the course of rehydration. We observed that ~52% of $Oxtr^{PBN}$ neurons responded to water, as measured by GCaMP fluorescence, although this is likely to be an underestimate because some neurons with low levels of GCaMP6 expression became photobleached. These results also suggest that Fos reveals only the subset of $Oxtr^{PBN}$ neurons with the greatest activity.

Chemogenetic activation of ~72% of $Oxtr^{PBN}$ neurons suppressed both NaCl and water intake, but activation of ~20% of caudal

Oxtr^{PBN} neurons following Oxt^{PVH} activation only mildly decreased water intake. Inactivating Oxt^{PVH} neurons predominantly increased NaCl intake. Taken together, these results suggest that Oxtr^{PBN} neurons provide an overall inhibitory effect on total fluid intake, with the amount of fluid intake and the type of fluid intake (NaCl and/or water) being dependent on the percentage of Oxtr^{PBN} neurons that are activated.

Results from inactivation studies suggest that Oxtr^{PBN} neurons are necessary for preventing excessive NaCl intake. In the case of dehydration, the body engages physiological mechanisms to reduce NaCl and retain water to prevent hypernatremia—for example, by inducing a dehydration-induced natriuresis^{36,37}. Our results suggest that Oxtr^{PBN} neurons are activated following rehydration to prevent excessive NaCl ingestion. In addition, Oxtr^{PBN} activation decreased food intake during dehydration, but not after fasting, suggesting that the decrease may be a result of salt (0.25%) in the food rather than its caloric content³⁸. In the case of hypertonic saline injection, hypernatremia is known to increase thirst and water intake^{9,12,39}, as well as to stimulate renal NaCl excretion⁴⁰. Our results suggest that Oxtr^{PBN} activation also decreases NaCl ingestion. Activation and inactivation studies revealed that Oxtr^{PBN} neurons did not alter NaCl intake after salt depletion and did not alter food intake except during dehydration, suggesting they are not involved in salt appetite or caloric-containing food consumption. Overall, our results suggest that activation of Oxtr^{PBN} neurons is essential for maintaining fluid homeostasis, as they decrease NaCl and/or water intake to prevent or attenuate hypervolemia and/or hypernatremia (Supplementary Fig. 10b).

The hypothalamus is an integrative center of the brain that coordinates responses to maintain homeostatic setpoints⁴¹. Whole-cell patch-clamp recordings have revealed increased firing of oxytocin-expressing neurons under hypertonic conditions and decreased firing in response to angiotensin II, which signals hypovolemic conditions⁴², suggesting that hypothalamic oxytocin-related neurons may be activated predominantly by hypovolemic hypertonic conditions. We expected that activating Oxt^{PVH} neurons would decrease NaCl intake; instead, we observed only a mild attenuation of water intake. A possible explanation is that Oxtr^{PBN} neurons are already engaged in preventing excessive NaCl intake, and further activation via Oxt^{PVH} stimulation provides only a small extra attenuation of total fluid intake. In addition, activating Oxt^{PVH} may release peripheral oxytocin and induce renal sodium excretion^{6–8}, which, in conjunction with a mild attenuation of water intake, may decrease ECF volume.

The NTS receives peripheral signals, including baroreceptor input, via inputs from cranial nerves IX and X, and is known to suppress fluid intake^{9,11}. We observed that activating NTS neurons, including CCK^{NTS} neurons, substantially reduced fluid intake, suggesting that NTS neurons may provide a large functional input to the PBN to reduce fluid intake. Although we did not demonstrate direct projections to Oxtr^{PBN} neurons, we observed Fos expression in ~33% of Oxtr^{PBN} neurons after nonspecific activation of the NTS and in ~19% of Oxtr^{PBN} neurons after activation of CCK neurons in the NTS, suggesting that Oxtr^{PBN} neurons are regulated by several distinct inputs from the NTS.

Overall, our results identify Oxtr as a marker for PBN neurons that are involved in regulating fluid intake. Studying the neural circuitry of fluid satiation may help to increase our understanding of body fluid homeostasis.

Methods

Methods, including statements of data availability and any associated accession codes and references, are available at <https://doi.org/10.1038/s41593-017-0014-z>.

Received: 28 November 2016; Accepted: 17 September 2017;
Published online: 13 November 2017

References

- Lee, H. J., Macbeth, A. H., Pagani, J. H. & Young, W. S. III Oxytocin: the great facilitator of life. *Prog. Neurobiol.* **88**, 127–151 (2009).
- Arletti, R., Benelli, A. & Bertolini, A. Oxytocin inhibits food and fluid intake in rats. *Physiol. Behav.* **48**, 825–830 (1990).
- Blevins, J. E., Eakin, T. J., Murphy, J. A., Schwartz, M. W. & Baskin, D. G. Oxytocin innervation of caudal brainstem nuclei activated by cholecystokinin. *Brain Res.* **993**, 30–41 (2003).
- Stricker, E. M. & Verbalis, J. G. Central inhibition of salt appetite by oxytocin in rats. *Regul. Pept.* **66**, 83–85 (1996).
- Rigatto, K., Puryear, R., Bernatova, I. & Morris, M. Salt appetite and the renin-angiotensin system: effect of oxytocin deficiency. *Hypertension* **42**, 793–797 (2003).
- Balment, R. J., Brimble, M. J. & Forsling, M. L. Release of oxytocin induced by salt loading and its influence on renal excretion in the male rat. *J. Physiol. (Lond.)* **308**, 439–449 (1980).
- Conrad, K. P., Gellai, M., North, W. G. & Valtin, H. Influence of oxytocin on renal hemodynamics and sodium excretion. *Ann. NY Acad. Sci.* **689**, 346–362 (1993).
- Verbalis, J. G., Mangione, M. P. & Stricker, E. M. Oxytocin produces natriuresis in rats at physiological plasma concentrations. *Endocrinology* **128**, 1317–1322 (1991).
- McKinley, M. J. & Johnson, A. K. The physiological regulation of thirst and fluid intake. *News Physiol. Sci.* **19**, 1–6 (2004).
- Geerling, J. C. & Loewy, A. D. Central regulation of sodium appetite. *Exp. Physiol.* **93**, 177–209 (2008).
- Johnson, A. K. & Thunhorst, R. L. The neuroendocrinology of thirst and salt appetite: visceral sensory signals and mechanisms of central integration. *Front. Neuroendocrinol.* **18**, 292–353 (1997).
- Verbalis, J. G. Disorders of body water homeostasis. *Best Pract. Res. Clin. Endocrinol. Metab.* **17**, 471–503 (2003).
- Gimpl, G. & Fahrenholz, F. The oxytocin receptor system: structure, function, and regulation. *Physiol. Rev.* **81**, 629–683 (2001).
- Fenselau, H. et al. A rapidly acting glutamatergic ARC →PVH satiety circuit postsynaptically regulated by α-MSH. *Nat. Neurosci.* **20**, 42–51 (2017).
- Carter, M. E., Soden, M. E., Zweifel, L. S. & Palmiter, R. D. Genetic identification of a neural circuit that suppresses appetite. *Nature* **503**, 111–114 (2013).
- Ohman, L. E. & Johnson, A. K. Lesions in lateral parabrachial nucleus enhance drinking to angiotensin II and isoproterenol. *Am. J. Physiol.* **251**, R504–R509 (1986).
- Callera, J. C. et al. GABA_A receptor activation in the lateral parabrachial nucleus induces water and hypertonic NaCl intake. *Neuroscience* **134**, 725–735 (2005).
- Edwards, G. L. & Johnson, A. K. Enhanced drinking after excitotoxic lesions of the parabrachial nucleus in the rat. *Am. J. Physiol.* **261**, R1039–R1044 (1991).
- Menani, J. V., De Luca, L. A. Jr & Johnson, A. K. Role of the lateral parabrachial nucleus in the control of sodium appetite. *Am. J. Physiol. Regul. Integr. Comp. Physiol.* **306**, R201–R210 (2014).
- Armbruster, B. N., Li, X., Pausch, M. H., Herlitze, S. & Roth, B. L. Evolving the lock to fit the key to create a family of G protein-coupled receptors potently activated by an inert ligand. *Proc. Natl. Acad. Sci. USA* **104**, 5163–5168 (2007).
- Jarvie, B. C. & Palmiter, R. D. HSD2 neurons in the hindbrain drive sodium appetite. *Nat. Neurosci.* **20**, 167–169 (2017).
- Rinaman, L. et al. Dehydration anorexia is attenuated in oxytocin-deficient mice. *Am. J. Physiol. Regul. Integr. Comp. Physiol.* **288**, R1791–R1799 (2005).
- Kinsman, B. et al. Osmoregulatory thirst in mice lacking the transient receptor potential vanilloid type 1 (TRPV1) and/or type 4 (TRPV4) receptor. *Am. J. Physiol. Regul. Integr. Comp. Physiol.* **307**, R1092–R1100 (2014).
- Han, S., Soleiman, M. T., Soden, M. E., Zweifel, L. S. & Palmiter, R. D. Elucidating an affective pain circuit that creates a threat memory. *Cell* **162**, 363–374 (2015).
- Davern, P. J. & McKinley, M. J. Brain regions influenced by the lateral parabrachial nucleus in angiotensin II-induced water intake. *Neuroscience* **252**, 410–419 (2013).
- Matsuda, T. et al. Distinct neural mechanisms for the control of thirst and salt appetite in the subfornical organ. *Nat. Neurosci.* **20**, 230–241 (2017).
- Johnson, A. K., Cunningham, J. T. & Thunhorst, R. L. Integrative role of the lamina terminalis in the regulation of cardiovascular and body fluid homeostasis. *Clin. Exp. Pharmacol. Physiol.* **23**, 183–191 (1996).
- Swanson, L. W. & Sawchenko, P. E. Hypothalamic integration: organization of the paraventricular and supraoptic nuclei. *Annu. Rev. Neurosci.* **6**, 269–324 (1983).
- Sutton, A. K. et al. Control of food intake and energy expenditure by Nos1 neurons of the paraventricular hypothalamus. *J. Neurosci.* **34**, 15306–15318 (2014).

30. Smith, K. S., Buccì, D. J., Luikart, B. W. & Mahler, S. V. DREADDS: use and application in behavioral neuroscience. *Behav. Neurosci.* **130**, 137–155 (2016).
31. Swanson, L. W. & Kuypers, H. G. The paraventricular nucleus of the hypothalamus: cytoarchitectonic subdivisions and organization of projections to the pituitary, dorsal vagal complex, and spinal cord as demonstrated by retrograde fluorescence double-labeling methods. *J. Comp. Neurol.* **194**, 555–570 (1980).
32. Menani, J. V. & Johnson, A. K. Cholecystokinin actions in the parabrachial nucleus: effects on thirst and salt appetite. *Am. J. Physiol.* **275**, R1431–R1437 (1998).
33. Roman, C. W., Derkach, V. A. & Palmiter, R. D. Genetically and functionally defined NTS to PBN brain circuits mediating anorexia. *Nat. Commun.* **7**, 11905 (2016).
34. Chen, Y., Lin, Y. C., Kuo, T. W. & Knight, Z. A. Sensory detection of food rapidly modulates arcuate feeding circuits. *Cell* **160**, 829–841 (2015).
35. Mandelblat-Cerf, Y. et al. Bidirectional anticipation of future osmotic challenges by vasopressin neurons. *Neuron* **93**, 57–65 (2017).
36. McKinley, M. J., Denton, D. A., Nelson, J. F. & Weisinger, R. S. Dehydration induces sodium depletion in rats, rabbits, and sheep. *Am. J. Physiol.* **245**, R287–R292 (1983).
37. Huang, W., Lee, S. L., Arnason, S. S. & Sjöquist, M. Dehydration natriuresis in male rats is mediated by oxytocin. *Am. J. Physiol.* **270**, R427–R433 (1996).
38. McKinley, M. J. Adaptive appetites for salted and unsalted food in rats: differential effects of sodium depletion, DOCA and dehydration. *Am. J. Physiol. Regul. Integr. Comp. Physiol.* **304**, R1149–R1160 (2013).
39. Kutschera, C. Effect of hypertonic saline injections and water deprivation on drinking, serum osmolality and gut water. *Physiol. Behav.* **1**, 259–268 (1966).
40. Huang, W., Lee, S. L. & Sjöquist, M. Natriuretic role of endogenous oxytocin in male rats infused with hypertonic NaCl. *Am. J. Physiol.* **268**, R634–R640 (1995).
41. Saper, C. B. & Lowell, B. B. The hypothalamus. *Curr. Biol.* **24**, R1111–R1116 (2014).
42. Stachniak, T. J., Trudel, E. & Bourque, C. W. Cell-specific retrograde signals mediate antiparallel effects of angiotensin II on osmoreceptor afferents to vasopressin and oxytocin neurons. *Cell Rep.* **8**, 355–362 (2014).
43. Benelli, A., Bertolini, A. & Arletti, R. Oxytocin-induced inhibition of feeding and drinking: no sexual dimorphism in rats. *Neuropeptides* **20**, 57–62 (1991).
44. Sanford, C. A. et al. A central amygdala CRF circuit facilitates learning about weak threats. *Neuron* **93**, 164–178 (2017).
45. Paxinos, G. & Franklin, K. B. J. *The Mouse Brain in Stereotaxic Coordinates* (Elsevier Academic Press, Waltham, MA, USA, 2013).
46. Owen, S. F. et al. Oxytocin enhances hippocampal spike transmission by modulating fast-spiking interneurons. *Nature* **500**, 458–462 (2013).
47. Tang, Y. et al. Oxytocin activation of neurons in ventral tegmental area and interfacicular nucleus of mouse midbrain. *Neuropharmacology* **77**, 277–284 (2014).
48. Mohammad, S. et al. Functional compensation between cholecystokinin-1 and -2 receptors in murine paraventricular nucleus neurons. *J. Biol. Chem.* **287**, 39391–39401 (2012).
49. Wang, F. et al. RNAscope: a novel in situ RNA analysis platform for formalin-fixed, paraffin-embedded tissues. *J. Mol. Diagn.* **14**, 22–29 (2012).
50. Liedtke, W. B. et al. Relation of addiction genes to hypothalamic gene changes subserving genesis and gratification of a classic instinct, sodium appetite. *Proc. Natl. Acad. Sci. USA* **108**, 12509–12514 (2011).
51. Resendez, S. L. et al. Visualization of cortical, subcortical and deep brain neural circuit dynamics during naturalistic mammalian behavior with head-mounted microscopes and chronically implanted lenses. *Nat. Protoc.* **11**, 566–597 (2016).
52. Zhou, P. et al. Efficient and accurate extraction of in vivo calcium signals from microendoscopic video data. Preprint at <https://arxiv.org/abs/1605.07266> (2016).

Acknowledgements

We thank B. Roth and K. Deisseroth for AAV plasmid constructs. M. Chiang assisted with animal husbandry. S. Tsang and K. Kafer helped to generate the *Oxtr^{Cre}* mice. We thank J. Chen for help with surgery for *Calca^{Cre/+}* experiments and C. Roman for help with surgery for *Cck^{Cre/+}* experiments. M. McKinley, B. Jarvie, C. Roman and members of the Palmiter lab provided helpful discussion and feedback. P.J.R. was supported by an Australian American Fellowship and a National Health and Medical Council of Australia CJ Martin Fellowship. C.A.C. was supported by a fellowship from Hope Funds for Cancer Research. R.D.P. was supported by a US National Institutes of Health grant (R01-DA24908). Inscopix provided the calcium-imaging equipment and supplies via their DECODE grant program.

Author contributions

P.J.R. and R.D.P. conceived and designed the study. P.J.R. performed and analyzed the experiments. S.I.R. and P.J.R. performed the immunohistochemistry and counting of cells. V.A.D. performed electrophysiological experiments. C.A.C. performed GCaMP6 studies. R.D.P. generated *Oxtr^{Cre}* mice and provided equipment and reagents. P.J.R. wrote the manuscript with input from R.D.P. and other authors.

Competing interests

The authors declare no competing financial interests.

Additional information

Supplementary information is available for this paper at <https://doi.org/10.1038/s41593-017-0014-z>.

Reprints and permissions information is available at www.nature.com/reprints.

Correspondence and requests for materials should be addressed to P.J.R. or R.D.P.

Publisher's note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Methods

Mice. Experiments were approved by the University of Washington Animal Care and Use Committee and performed in accordance with the US National Institutes of Health Guide for the Care and Use of Laboratory Animals. Mouse lines were bred onto a C57Bl/6J background and backcrossed >6 generations. The following mouse lines were used in these experiments: heterozygous *Oxtr^{Cre/+}* and *Calca^{Cre/+}* (developed in our laboratory¹³); heterozygous *Cck^{Cre/+}* and *Oxt^{Cre/+}* mice (Jackson Laboratory), and *Oxt^{Cre/+}::Oxt^{Cre/+}* mice. The *Oxt^{Cre}* and *Oxt^{Cre}* mice lines were crossed to Cre-dependent *Gt(ROSA)26Sor^{tm14(CAG-tdTomato)Hze/l}* mice (Allen Institute, Ai14) to reveal expression patterns.

Most behavioral experiments were performed on male mice (7–14 weeks old at start of experimentation). Combined cohorts of male and female mice were used in the following experiments: Fos study in *Oxtr^{Cre/+}* mice following fluid deprivation; *Oxtr^{Cre/+}* mice injected with non-specific hM₃Dq or DsRed in the NTS; behavioral studies on *Oxt^{Cre/+}* mice, including *Oxt^{Cre/+}* mice implanted with cannulas; and *Calca^{Cre/+}* mice. In these experiments, female mice were distributed evenly between experimental and control groups and data were combined, as we found no significant difference in water or saline intake, as previously reported in the literature for rats⁴³.

Animals in each litter were randomly assigned to either experimental or control groups. Before stereotaxic surgery, mice were group housed and maintained on a rodent diet (Picolab, number 5053) with water available ad libitum in a 12-h light:dark cycle at 22 °C. Mice were at least 7 weeks old before surgery. Following surgery, mice were single housed and allowed to recover for at least 1 week before experimentation. All fluid and food experiments were performed with at least two cohorts of mice and data were combined, unless otherwise stated.

During salt-related experiments, mice were fed on a sodium-deficient diet (<0.02% NaCl, Diet #99091603, Research Diet) and had access to saline and water in tubes, unless otherwise noted. At other times, such as during feeding experiments in BioDAQ chambers, mice were fed a control rodent diet (Diet D12450, Research Diets). Some mice were also tested on a liquid diet, Ensure (Abbott Laboratories).

Generation of *Oxtr^{Cre/GFP}* mice. The 5' arm (~5 kb with PacI and Sall sites at each end) and 3' arm (~5 kb with PmeI and NotI sites at each end) of *Oxtr* gene were amplified from a C57Bl/6 BAC clone by PCR using Phusion Polymerase (New England Biolabs) and cloned into polylinkers of a targeting construct that contained *ires-mnCre:GFP*, a *frt*-flanked *Sv40Neo* gene for positive selection, and HSV thymidine kinase and *Pgk*-diphtheria toxin A chain genes for negative selection (see Supplementary Fig. 1). The *ires-mnCre:GFP* cassette has an internal ribosome entry sites followed by a myc-tag and nuclear localization signal at the N terminus of Cre recombinase fused to green fluorescent protein. The construct was electroporated into G4 ES cells (C57Bl/6 × 129 Sv hybrid) and correct targeting was determined by Southern blot of DNA digested with HindIII using a ³²P-labeled probe downstream of the 3' arm of the targeting construct. Thirteen of 84 clones analyzed were correctly targeted. One clone that was injected into blastocysts resulted in good chimeras that transmitted the targeted allele throughout the germline. Progeny were bred with *Gt(Rosa)26Sor-FLP* FLP recombinase mice to remove the SV-Neo gene. Mice were then continuously backcrossed to C57Bl/6 mice.

Virus production. AAV1-DIO-hM₃Dq:mCherry and AAV1-DIO-hM₄Di:mCherry (both driven by the human *SYNAPSIN* promoter) DNA plasmids were provided by B. Roth (University of North Carolina at Chapel Hill); AAV1-DIO-YFP, AAV1-DIO-ChR2:YFP (both driven by the human *SYNAPSIN* promoter) and AAV1-DIO-mCherry (driven by the *Efla* promoter) DNA plasmids were provided by K. Deisseroth (Stanford University). The AAV1-DIO-GFP:TetTox (driven by the CBA promoter), AAV1-DIO-synaptophysin:mCherry (driven by the *Efla* promoter) and AAV1-DIO-GCaMP6m (driven by the CBA promoter) were generated as described^{15,24,44}. The non-selective AAV8-hM₃Dq:mCherry (driven by the human *SYNAPSIN* promoter) was a gift from B. Roth (Addgene plasmid #50474). The non-selective AAV1-DsRed (driven by the CBA promoter) was developed in our laboratory. AAV vectors were prepared in human embryonic kidney (HEK293T) cells with AAV serotype 1 (AAV1), purified by multi-step sucrose- and CsCl-gradient centrifugation and resuspended in phosphate-buffered solution at a titer of ~2 × 10⁹ viral genomes/μl. Aliquots were stored at -80 °C before use.

Stereotaxic surgery. Mice were anesthetized with isoflurane, placed on a stereotaxic frame (David Kopf Instruments) and injected with ketoprofen (5 mg/kg, ip) for analgesia. Stereotaxic coordinates were normalized for the anterior-posterior plane by a correction factor ($F = \text{distance between bregma and lambda}4/4.21$)⁴⁵. Viruses were injected (500 nl bilaterally) via glass pipettes using the Nanoject II Auto-Nanoliter Injector (3-000-204; Drummond Scientific Company). The viruses were injected according to the following coordinates: PVH (AP: -0.2; ML: ±0.25; DV: -5); PBN (AP: -5.2; ML: ±1.35; DV: -3.1); NTS (AP: -7.4; ML: ±0.35; DV: -5.2) or, in *Cck^{Cre/+}* mice, (AP: -6.8; ML: ±0.35; DV: -5.2 at 10° holder angle). Mice were given >2 weeks to recover before experimentation to allow viral expression.

Infusion into the PBN was performed via bilateral cannulas (double cannula guide; 26 gauge, 2.7 mm apart, cut 5 mm below pedestal; PlasticsOne), which were

inserted according to coordinates (AP: -5.2; ML: ±1.35; DV: -3.1) and affixed to the skull with C&B Metabond (Parkell) and dental acrylic. Prior to and between infusions, cannulas were kept patent by inserting a dummy double cannula (0.2 mm width; 2.7 mm apart; fit 5 mm) and small round-top dust caps. Infusions were performed using an internal double injector (33 gauge; 2.7 mm apart; 0.2 mm width) for a cannula guide.

Tissue processing. Following experimentation, mice were anesthetized with Beuthanasia 0.2 ml ip (effective content 320 mg/kg pentobarbital; Schering-Plough) and perfused transcardially with phosphate-buffered saline (PBS), followed by 4% paraformaldehyde (Electron Microscopy Sciences) in PBS. Brains were removed and placed in paraformaldehyde at 4 °C overnight, and then cryoprotected in 30% sucrose in PBS overnight, then OCT (Fisher HealthCare) and kept at -80 °C before processing. Coronal sections of 30 μm thickness were cut from the brain on a cryostat. For all Fos studies, every third section was collected (90 μm apart) for quantification. For confirmation of viral targeting, every fifth brain section was mounted onto glass slides (Fisherbrand Superfrost Plus microscope slides, Fisher Scientific) and coverslipped with Dapi Fluoromount G (Southern Biotech), and remaining sections were collected in PBS for further processing as required.

Although *Oxtr^{Cre/+}* mice have GFP fused to Cre, we were unable to visualize GFP even after anti-GFP antibody staining; hence *Oxtr^{PBN}* neurons were visualized by genetic crosses with Ai14 mice, which allows expression of TdTomato in *Oxtr* neurons.

Slice optogenetics and electrophysiology. Acute 250-μm coronal slices that included the PBN were prepared from 2–6-month-old mice, which were deeply anesthetized in their housing room before decapitation. Slice procedure and recordings were performed essentially as previously described³³. Neurons of interest were identified by GFP or mCherry expression (CGRP^{PBN} and *Oxtr^{PBN}* neurons, respectively). To observe neuronal activity under minimally invasive conditions, endogenous spike activity and optogenetically evoked spikes were recorded in loose-patch cell-attached configuration with patch pipettes filled with the same artificial cerebrospinal fluid used for slice perfusion (ACSF, in mM: NaCl 115, KCl 3, CaCl₂ 2, MgCl₂ 1, NaH₂PO₄ 1, NaHCO₃ 25 and D-glucose 11; mOsm 295, pH 7.4 when aerated with carbogen, 33 °C) and 0 holding current. Synaptic currents were recorded under voltage-clamp conditions and patch pipettes filled with intracellular solution (in mM: 100 cesium methanesulfonate, 25 CsCl, 2 MgCl₂, 10 HEPES, 0.4 EGTA, 4 ATP, 0.4 GTP, 10 phosphocreatine, mOsm 295, pH 7.3). Light-evoked action potentials and synaptic currents were initiated by optical activation of ChR2 with 2–5-ms pulses of blue light (up to 3 mW optic power) either from a 473-nm laser (Laserglow) via an optic fiber positioned over the slice, or from a high power 460 nm LED (UHP-LED, Prizmatix) via a microscope objective. Synaptic latency was measured as the time between onset of the blue-light pulse and the onset of synaptic current. Synaptic jitter was calculated as the s.d. in variation of synaptic latency over multiple trials (25–50) in a particular neuron. Currents were elicited at 10-s interval between successive trials, recorded at 2–5-kHz bandwidth, digitized at 20 kHz and acquired by pCLAMP10 software (Molecular Devices). Drugs were dissolved in ACSF and delivered to slices by local perfusion via a three-barrel system positioned over the slice. The drug application was gravity driven and on-off timing was manually controlled. Where indicated, AMPA and NMDA glutamate receptors were inhibited by a cocktail of CNQX (20 μM, Tocris) and D-AP5 (50 μM, Tocris) added to ACSF, and GABA_A receptors were inhibited by picrotoxin (100 μM, Tocris). Other drugs used include the following: *Oxtr* agonist, TGOT (200 nM; Bachem, H-7710)⁴⁶; specific *Oxtr* antagonist, atosiban (1 μM; Sigma-Aldrich, A3480)⁴⁷; and CCK-8 (30 nM; Bachem, H-2080)⁴⁸. Overall, recordings were made from 45 *Oxtr^{PBN}* neurons from 47 PBN slices derived from 26 *Oxtr^{Cre/+}* mice (some crossed with *Oxt^{Cre/+}* mice), of which 11 were male and 15 were female; and from 7 CGRP^{PBN} neurons from 7 PBN slices derived from 7 *Calca^{Cre/+}* mice (all male).

Immunohistochemistry. *Fos* studies. Immunohistochemistry was performed on free-floating sections. Sections underwent three 5-min washes in PBST (phosphate-buffered solution with 0.1% Triton X-114 (Sigma-Aldrich)) and were placed in a blocking solution (PBST with 3% normal donkey serum (NDS; Jackson ImmunoResearch)) for 1 h at room temperature (20–22 °C) to prevent nonspecific binding. For the primary antibody, sections were incubated with rabbit anti-Fos (1:2,000; Cell Signaling Technology, number PC38) in 3% NDS in PBST overnight at 4 °C. After three 5-min washes in PBST, the samples were incubated in the dark with a Cy5-conjugated (far red) donkey anti-rabbit IgG (1:500; Jackson ImmunoResearch, number 711-175-152) in 3% NDS in PBST for 1 h at 20–22 °C. The samples were then washed three times (5 min each) in PBS, before being mounted onto glass slides in PBS and coverslipped using Dapi Fluoromount-G.

hM₃Dq, *hM₄Di* and *synaptophysin* studies. *Oxtr^{Cre/+}*, *Oxt^{Cre/+}*, *Oxt^{Cre/+}::Oxtr^{Cre/+}*, *Calca^{Cre/+}* and *Cck^{Cre/+}* mice injected with AAV1-DIO-hM₃Dq:mCherry, AAV1-DIO-hM₄Di:mCherry, control AAV1-DIO-mCherry and AAV-DIO-synaptophysin:mCherry underwent anti-DsRed immunohistochemistry staining to amplify the fluorescent protein signal. To examine neuronal activation, we examined Fos expression in hM₃Dq- and control mCherry-injected mice after

injection with CNO 2 h before perfusion. The primary antibodies were rabbit anti Ds-Red (1:1,000; (Clontech) Takara Bio USA, number 632496) and goat anti-Fos (1:500; Santa Cruz Biotechnology); the secondary antibodies were Alexa Fluor 594-conjugated donkey anti-rabbit IgG (1:500; Jackson ImmunoResearch, number 711-585-152) and Cy5-conjugated donkey anti-goat IgG (1:500; Jackson ImmunoResearch, number 705-175-147).

TetTox studies. *Oxtr^{Cre/+}*, *Oxtr^{Cre/+}* and *Oxtr^{Cre/+}::Oxtr^{Cre/+}* mice injected with AAV1-DIO-GFP:TetTox and AAV1-DIO-YFP underwent anti-GFP immunohistochemistry staining using a similar histological procedure to amplify the fluorescent protein signal. The primary antibody was chicken anti-GFP (1:10,000; Abcam, number 13970); the secondary antibody was Alexa Fluor 488-conjugated donkey anti-chicken IgG (1:500; Jackson ImmunoResearch, number 703-545-155).

CGRP antibody studies. To investigate coexpression of *Oxtr* and CGRP in PBN, we assessed PBN sections from *Oxtr^{Cre/+}::Ai14* mice. The primary antibody was mouse anti-CGRP (1:5,000; Abcam, ab1887); the secondary antibody was Cy5-conjugated anti-mouse IgG (1:400; Jackson ImmunoResearch, number 715-175-150).

RNAscope. We performed in situ hybridization (ISH) using the RNAscope assay⁴⁹ on brain tissue collected from *Oxtr^{Cre/+}::Ai14* and *Cck^{Cre/+}* mice. Mice were perfused as described above then embedded gradually through a series of 10%, 20% and 30% sucrose followed by OCT (Fisher HealthCare). Brains were cut coronally at 10 μ m thickness, mounted and stored at -80°C before processing. On the day of processing, sections were thawed at $20\text{--}22^{\circ}\text{C}$ for ~ 30 min before performing ISH according to the manufacturer's protocol (Advanced Cell Diagnostics). We used probes for *Oxtr* (Mm-Oxtr-C3 probe, 1:50 dilution) and *Fos* (Mm-Fos-C2 probe, 1:50 dilution). Following ISH, slides were coverslipped and imaged as described. For *Oxtr^{Cre/+}::Ai14* mice, we imaged *TdTomato* fluorescence, then matched sections after ISH ($n = 3$). For *Cck^{Cre/+}* mice, we imaged staining for *Oxtr* and *Fos* mRNA after performing ISH ($n = 3$).

Microscopy. For Fos, in situ and coexpression studies, brain sections were imaged on an Olympus Fluoview FV1200 confocal microscope (Shijuku). To confirm targeted injections, brain sections were imaged using the Nikon upright epifluorescent Eclipse E600 microscope (Minato) or Keyence Fluorescence Microscope BZ-X700. ImageJ, a program for optimizing brightness and contrast, was used to color images—for example, *Oxtr^{Cre/+}::Ai14* cells red and AAV1-DIO-YFP-injected neurons green. Images were minimally processed to enhance brightness and contrast for optimal representation. Following imaging, any mouse whose targeted injection site was missed or demonstrated very sparse expression (≤ 6 fluorescent neurons/section), suggesting inadequate injection, was excluded from experimental analysis. In addition, any mouse that was unilaterally injected was included in experimental analyses for stimulatory (one unilateral injection in each group of hM₃Dq-injected *Oxtr^{PBN}* and *Oxtr^{PVH}* mice) and control groups, but was excluded from inhibitory (TetTox- and hM₄Di-injected) groups. For infusion experiments, mice whose targeted injection was missed were excluded (two mice).

Fos experiments. For salt-depletion and fluid-deprivation experiments, *Oxtr^{Cre/+}::Ai14* mice were single-housed and placed on a sodium-deficient diet and given access to both 0.5 M NaCl and water for 5 d of habituation. For salt depletion, mice were divided into three groups: (1) salt returned, (2) salt depleted and (3) control ($n = 3$ or 4 per group). Mice in group 1 were injected with furosemide (5 mg ml⁻¹) daily for 2 d and denied access to saline (but not water), to develop a salt appetite⁵⁰. On day 3, saline was returned and mice were perfused 2 h later (during the light cycle). Mice in group 2 underwent a similar protocol; however, saline was not returned before perfusion. Mice in group 3 had no furosemide challenge and were perfused on day 3.

For fluid deprivation, mice were divided into two groups: (1) fluid returned and (2) fluid deprived ($n = 3$ or 4 per group). Mice in group 1 were deprived of saline and water for ~ 24 h, and were perfused 2 h after fluid was returned (during the light cycle). Mice in group 2 were also deprived of saline and water for ~ 24 h, which were not returned before perfusion.

For hypertonic saline injections, mice were single-housed for 5 d with ad libitum access to food and water, and divided into two groups: (1) 1 M saline (10 μ g l⁻¹ body weight) injection and (2) normal saline injection ($n = 3$ or 4 per group). Each mouse was injected with saline and perfused 2 h later (during the light cycle).

Quantification of Fos expression was performed on six 30- μ m-thick coronal brain sections 90 μ m apart, ranging from bregma -5.1 to -5.5 (encompassing the major portion of the PBN where *Oxtr* is expressed). The investigator who quantified Fos was blinded to the identity of the conditions. Given that there was differential activation throughout the PBN, the sections were evenly divided into caudal, middle and rostral regions. An estimate of total *Oxtr*-expressing neurons was made by multiplying by 3.

To examine Fos expression in *Oxtr^{PBN}*, *CGRP^{PBN}*, *Oxtr^{PVH}*, *CCK^{NTS}* or NTS neurons following experimentation, mice were injected with CNO and perfused 2 h later.

Calcium imaging. Mice were prepared for calcium imaging as described⁵¹. Briefly, 3 weeks after AAV1-DIO-GCaMP6m and AAV1-DIO-hM₃Dq:mCherry viral injection, mice were anesthetized (as described above) and implanted with a microscope lens (6.1 mm length, 0.5 mm diameter; Inscopix, catalog #100-000588) with assistance of a ProView implant kit (Inscopix, catalog #100-000754) that allowed visualization of the fluorescent activity during the lens implantation. Because basal fluorescence from *Oxtr* neurons was low, we treated the mice with CNO before lens implantation to facilitate visualization and lens placement. The lens was targeted to be $\sim 200\text{--}300$ μ m above the neurons using the following coordinates: -4.80 mm posterior to bregma, -1.40 mm lateral from midline, and -3.00 mm ventral to skull surface. One week after lens implantation, mice were anesthetized and a baseplate (Inscopix, catalog #100-000279) was implanted above the lens. The baseplate provides an interface for attaching the miniature microscope during calcium imaging experiments, but at other times a baseplate cover (Inscopix, catalog #100-000241) was attached to prevent damage to the microendoscope lens. Calcium fluorescence was recorded at five frames per second, 200-ms exposure time, and 50% LED power using a miniature microscope from Inscopix (nVista). The recording parameters were based on pilot studies that demonstrated the least amount of photobleaching while allowing sufficient detection of fluorescent activity. We used Ethovision (XT 10, Noldus Technology) to trigger and synchronize calcium recordings with behavioral video recordings.

Water deprivation and rehydration. Mice were water-deprived for 24 h. On the experimental day, mice were briefly anesthetized with isoflurane to attach the microscope, and then allowed to acclimate in their home cage for 1 h. After the acclimation period, baseline fluorescence was recorded for 30 s, a water bottle was placed in the cage, and fluorescence was continuously recorded for 10 min. On separate test days, we placed an empty bottle or a bottle with Ensure in the cage. We adjusted the focus of the microscope between tests, accounting for slightly different total numbers of neurons between different test days. Calcium recording files were spatially downsampled (factor of 4), motion-corrected (Inscopix, Mosaic v1.2), and fluorescent traces from individual neurons were extracted using constrained non-negative matrix factorization for microendoscopic data (CNMF-E)⁵². The key parameters used for CNMF-E were: l , 7; l_n , 14; P_{min} , 10; L_{min} , 0.85 (ref. 52). We then normalized (0 to 1) individual fluorescence traces taken from the entire 10-min recording period. Photobleaching was apparent during the recording session, so we were unable to adequately measure changes in activity over extended periods of time (for example, 10-min session); instead, we analyzed the change in fluorescence activity for 5 s before and 5 s during each bout. Bouts were defined as uninterrupted mouth contact with the water spout, and the beginning of an inter-bout interval was > 10 s of not contacting the spout. The data from every bout were averaged for each neuron across the 10-min recording session. 'Activated neurons' were defined as neurons that had an average fluorescence (after time point 0) of > 2 s.d. above baseline (baseline = average fluorescence from -5 to 0 s). Following the recording session, we injected mice with CNO, which aided in identifying all the neurons. These rehydration studies were conducted during the first hour of the dark cycle.

CNO-induced activation. Mice were briefly anesthetized with isoflurane to attach the microscope, then allowed to acclimate in their home cage for 1 h. After acclimation, we recorded baseline fluorescence activity for 30 s, followed by an ip injection of CNO (1 mg/kg). We non-continuously recorded (20 s for each time point) fluorescence at 5, 10, 15, 20, 25, 30, 45, 60 and 120 min after CNO injection. The calcium recording files were spatially downsampled (factor of 2), motion-corrected, and fluorescent traces were extracted using individual component analysis and principal component analysis (Inscopix, Mosaic v1.2). The change in fluorescence ($\Delta F/F$) was calculated as $(F - F_0)/F_0$, where F_0 was the average fluorescence 30 s before injection and F was the average fluorescence during a particular time point. These studies were conducted during the light cycle.

Food, water and saline intake. For acute feeding assays, mice were placed in BioDAQ chambers (Research Diets) which measured food intake electronically. Mice were individually housed, and water and body weight were measured manually. Mice were supplied with a rodent diet (D12450B, Research Diets), habituated to cages for 5–7 d and habituated to saline injections for 2–3 d. To measure food intake during the dark cycle, mice were injected with CNO 30 min before lights out and had access to food removed until lights out. To measure refeeding after a fast, food was removed for 24 h, then mice were injected with CNO 30 min before the return of food (in the morning). To measure food intake during the light cycle, mice were injected with CNO in the morning, then denied access to food for 30 min to allow time for the CNO to take effect. The experimenter was not blinded to the identity of the experimental versus control groups.

For drinking and salt-related studies, mice had access to both water and saline, and were placed on a sodium-depleted diet (diet #99091603, Research Diets), unless otherwise stated, to allow accurate measurement of both fluid and salt

intake. Tubes were placed into angled ports at the front of a cage and weighed manually (in grams; converted to milliliters), taking care to prevent dripping.

For TetTox-injected mice, baseline salt intake was monitored at three different concentrations (0.075, 0.3 and 0.5 M) for 3 d each (after 1 d of habituation); for subsequent experiments, a saline concentration of 0.3 M was used, unless otherwise stated. The order of experiments was baseline food and/or saline studies, 48-h salt depletion, 24-h fluid deprivation, hypertonic (0.5 M) saline ip, mannitol (1 M) ip and PEG 30% subcutaneous injections (these last three were randomly ordered). All these experiments were performed at the start of the dark cycle, unless otherwise noted. Recovery time was at least 7 d following salt depletion, and at least 3 d following other experiments.

For baseline fluid experiments in *Oxtr^{Cre/+}* and *Oxt^{Cre/+}* mice, we compared CNO versus vehicle injections in hM₃Dq- and mCherry-injected mice, and found no significant difference in fluid intake following vehicle injection. Given that there were multiple fluid intake experiments, we limited the number of experiments performed on individual mice by injecting only CNO and comparing fluid intake in hM₃Dq- versus mCherry-injected mice. We observed a difference in NaCl intake between *Oxtr^{Cre/+}* and *Oxt^{Cre/+}* mice, which is likely due to a difference in mouse strains obtained from different sources, so we ensured matched littermates were used for controls in all experiments. In *Oxt^{Cre/+}* mice, one hM₃Dq-injected mouse appeared sick 2 d before PEG injection, so it was perfused and not included in that experiment.

Given that mice underwent a series of fluid intake experiments, we also compared daily water and 0.3 M NaCl intake from the start of experimentation (just before the first study) to the end of experimentation (in final week of fluid intake studies). Salt and fluid deprivation were performed as described in the "Fos experiments" section. For hM₃Dq-, hM₄Di- and mCherry-injected mice, CNO (1 mg kg⁻¹) ip was injected 30 min before returning fluid. Fluid was returned ~15 min after the start of the dark cycle. For all deprivation experiments, we observed that mice would typically drink a large proportion in the first 15–30 min of the experiment, so we reported the first 2 h in 15-min intervals, unless otherwise stated. Baseline CNO and vehicle (normal saline) injections were also performed 30 min before returning fluid.

Hypertonic (0.5 M) saline and 1 M mannitol were injected ip ~10 min before CNO injection, whereas 30% PEG was injected subcutaneously ~30 min before CNO injection to allow extra time to diffuse. In general, these experiments showed increased differentiation of fluid intake over a longer time period, so we reported 4 h in 1-h intervals, unless otherwise stated. For liquid diet (Ensure) experiments, mice were habituated to Ensure and water for 2 d and then deprived of Ensure for 24 h before experimentation.

A separate cohort of mice was used to test limited Ensure intake and fluid intake in the absence of food. For the limited Ensure intake protocol, we initially returned a small quantity of Ensure (1.6 ml or 0.7 ml) after 24-h deprivation; at the end of experimentation, we returned ad libitum Ensure. For fluid intake in the absence of food, we repeated the protocol for 24-h dehydration, but removed food during the experimental period.

A separate cohort of mice was also used to test dehydration-induced food intake. Mice were habituated to BioDAQ chambers and supplied with a rodent diet (D12450B). On the day of experimentation, water and food were removed 7 h before lights out, then food (but not water) was returned at the start of the dark cycle. CNO was injected 30 min before experiments.

Intra-PBN infusions were performed during the light cycle. Infusions were performed using CMA-100 microinjection pump (Bioanalytical Systems)

over 5 min. Fluid was returned 5 min after infusion and intake measured for 2 h.

For *Calca^{Cre/+}* mice, we performed baseline fluid, rehydration and salt depletion studies, as described above. Rehydration was performed with 0.3 M NaCl and water; baseline fluid and salt depletion experiments were performed with 0.5 M NaCl and water. For *Cck^{Cre/+}* mice and nonspecific hM₃Dq-injected mice, we performed rehydration experiments with 0.3 M NaCl and water in hM₃Dq versus control mice.

Pharmacological injections. The following agents were prepared in sterile 0.9% saline: CNO (Sigma-Aldrich; C0832), polyethylene glycol (30% v/v; 20000 MW; Sigma-Aldrich; P2263). The following agents were prepared in sterile water: hypertonic NaCl (0.5 M; Fisher Scientific), mannitol (1 M; Sigma-Aldrich; M9647) and furosemide (5 mg ml⁻¹; Hospira). Polyethylene glycol was injected subcutaneously at 0.5 ml per mouse; all other compounds were injected intraperitoneally, including CNO, hypertonic NaCl and mannitol (10 μl g⁻¹ body weight), and furosemide (8 μl g⁻¹ body weight). CNO (1 mM) was also infused intra-PBN.

Statistics and figure preparation. Data analysis and generation of histograms were performed using GraphPad Prism Version 6.01 for Windows (GraphPad Software). Results are expressed as mean ± s.e.m. Statistical significance was determined by different tests appropriate for each dataset: for comparing the means of two groups, unpaired two-tailed Student's *t* test; for comparing the means of three or more groups, a one-way ANOVA with Tukey's post hoc tests; for correlation studies, a Pearson product-moment correlation; for comparing food or fluid intake over time, a repeated measures two-way ANOVA with Sidak's post hoc tests, unless otherwise noted. Three-way mixed design ANOVAs were performed using IBM SPSS Statistics for Windows v.20 (IBM). If Mauchly's test of sphericity was violated, a Greenhouse-Geisser correction was applied; if significant interaction was determined, a simple two-way interaction was performed with statistical significance accepted at a Bonferroni-adjusted α level of 0.025. We also tested for equality of variance (Brown-Forsythe test for one-way ANOVAs; or Levene's test of equality of variances). Data distribution was assumed to be normal, but this was not formally tested. *****P* < 0.0001; ****P* < 0.001; ***P* < 0.01; **P* < 0.05. Calcium fluorescence data were analyzed using OriginPro v.2016 (OriginLab).

A power analysis was performed for an effective sample size using <http://powerandsamplesize.com>. Based on a pilot study for fluid deprivation, we used a mean of 1.8 and s.d. of 0.4. Assuming a significance level of 0.05 and power of 0.8, we calculated a sample size of 7 per group if means were 1.5-fold different with a two-tailed Student's *t* test. Data and figures were exported into Adobe Illustrator CS6 (Adobe Systems) to prepare figures. Images of sagittal mouse brain were taken from the Motifolio toolkit.

Supplementary statistical analyses and methods checklist are provided in Supplementary Table 2 and the Life Sciences Reporting Summary.

Life Sciences Reporting Summary. Further information on experimental design and reagents is available in the Life Sciences Reporting Summary.

Code availability. No code was written by authors.

Data availability. The data that support the findings of this study are available from the corresponding author upon reasonable request.

Life Sciences Reporting Summary

Nature Research wishes to improve the reproducibility of the work that we publish. This form is intended for publication with all accepted life science papers and provides structure for consistency and transparency in reporting. Every life science submission will use this form; some list items might not apply to an individual manuscript, but all fields must be completed for clarity.

For further information on the points included in this form, see [Reporting Life Sciences Research](#). For further information on Nature Research policies, including our [data availability policy](#), see [Authors & Referees](#) and the [Editorial Policy Checklist](#).

► Experimental design

1. Sample size

Describe how sample size was determined.

See Methods - Statistics and figure preparation section - paragraph 2.
A power analysis was performed for an effective sample size using <http://powerandsamplesize.com>. Based on a pilot study for fluid deprivation, we used a mean of 1.8 and standard deviation of 0.4. Assuming a significance level of 0.05 and power of 0.8, we calculated a sample size of 7 per group if means were 1.5-fold different with a two-tailed Student's t-test.

2. Data exclusions

Describe any data exclusions.

See Methods - Microscopy section.
Following imaging, any mouse whose targeted injection site was missed or demonstrated very sparse expression (≤ 6 fluorescent neurons/section), suggesting inadequate injection, was excluded from experimental analysis. In addition, any mouse that was unilaterally injected was included in experimental analyses for stimulatory (1 unilateral injection in each group of hM3Dq-injected OxtRPBN and OxtPVH mice) and control groups, but was excluded from inhibitory (TetTox- and hM4Di-injected) groups. For infusion experiments, mice whose targeted injection was missed were excluded (2 mice).

3. Replication

Describe whether the experimental findings were reliably reproduced.

See Methods - Mice section - paragraph 3.
All fluid and food experiments were performed with at least two cohorts of mice and data were combined, unless otherwise stated.

4. Randomization

Describe how samples/organisms/participants were allocated into experimental groups.

See Methods - Mice section - paragraph 3.
Animals in each litter were randomly assigned to either experimental or control groups.

5. Blinding

Describe whether the investigators were blinded to group allocation during data collection and/or analysis.

See Methods - Fos experiments - paragraph 4; and Food and saline intake - paragraph 1.
1) The investigator who quantified Fos was blinded to the identity of the conditions.
2) The experimenter was not blinded to the identity of the experimental versus control groups.

Note: all studies involving animals and/or human research participants must disclose whether blinding and randomization were used.

6. Statistical parameters

For all figures and tables that use statistical methods, confirm that the following items are present in relevant figure legends (or in the Methods section if additional space is needed).

n/a Confirmed

- The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement (animals, litters, cultures, etc.)
- A description of how samples were collected, noting whether measurements were taken from distinct samples or whether the same sample was measured repeatedly
- A statement indicating how many times each experiment was replicated
- The statistical test(s) used and whether they are one- or two-sided (note: only common tests should be described solely by name; more complex techniques should be described in the Methods section)
- A description of any assumptions or corrections, such as an adjustment for multiple comparisons
- The test results (e.g. P values) given as exact values whenever possible and with confidence intervals noted
- A clear description of statistics including central tendency (e.g. median, mean) and variation (e.g. standard deviation, interquartile range)
- Clearly defined error bars

See the web collection on [statistics for biologists](#) for further resources and guidance.

► Software

Policy information about [availability of computer code](#)

7. Software

Describe the software used to analyze the data in this study.

See Methods - Statistics and figure preparation - paragraph 1
Data analysis and generation of histograms were performed using GraphPad Prism Version 6.01 for Windows.
Three-way mixed design ANOVA were performed using IBM SPSS Statistics for Windows v.20.
Calcium fluorescence data was analyzed using OriginPro v. 2016.

For manuscripts utilizing custom algorithms or software that are central to the paper but not yet described in the published literature, software must be made available to editors and reviewers upon request. We strongly encourage code deposition in a community repository (e.g. GitHub). *Nature Methods* [guidance for providing algorithms and software for publication](#) provides further information on this topic.

► Materials and reagents

Policy information about [availability of materials](#)

8. Materials availability

Indicate whether there are restrictions on availability of unique materials or if these materials are only available for distribution by a for-profit company.

No unique materials were used.

9. Antibodies

Describe the antibodies used and how they were validated for use in the system under study (i.e. assay and species).

See Methods - immunohistochemistry section.
The ordering information for the antibodies used are all referenced. The companies provide validation data for histological staining of fixed tissue.

10. Eukaryotic cell lines

a. State the source of each eukaryotic cell line used.

N/A

b. Describe the method of cell line authentication used.

N/A

c. Report whether the cell lines were tested for mycoplasma contamination.

N/A

d. If any of the cell lines used are listed in the database of commonly misidentified cell lines maintained by [ICLAC](#), provide a scientific rationale for their use.

N/A

► Animals and human research participants

Policy information about [studies involving animals](#); when reporting animal research, follow the [ARRIVE guidelines](#)

11. Description of research animals

Provide details on animals and/or animal-derived materials used in the study.

See Methods - Mice section - paragraphs 1 & 2 for details.

Policy information about [studies involving human research participants](#)

12. Description of human research participants

Describe the covariate-relevant population characteristics of the human research participants.

N/A